BSEM News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BS

Mkt Cap

$39.1M

Volume

27.96K

Loading chart

BS

BSEMBioStem Technologies, Inc. Common Stock

BSEM

Pay with—

Available Balance0.00

BS

Mkt Cap

$39.0M

Volume

27.96K

Next Earnings

N/A

Chart Earnings News About Insider Filings

BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and PremierBioStem Technologies announced that its VENDAJE and VENDAJE AC placental-derived wound care products have been added to existing contracts with Vizient and Premier, the two largest Group Purchasing Organizations in the U.S. This marks the first GPO contract coverage for these products and is expected to significantly expand hospital access and support the company's commercial strategy.GlobeNewswire Inc. · Sep 4, 2026

BioStem Technologies Announces Nasdaq UplistingBioStem Technologies Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allograft products, announced that Nasdaq has approved its common stock for listing on The Nasdaq Capital Market. Trading under ticker symbol 'BSEM' is expected to begin on August 7, 2026. The uplisting is expected to expand the company's access to capital, improve market visibility and liquidity, and enhance its ability to attract talent.GlobeNewswire Inc. · Aug 6, 2026

BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare ConferenceBioStem Technologies (OTC: BSEM), a MedTech company specializing in perinatal tissue-derived products for advanced wound care, announced that company management will present at the 46th Annual TD Cowen Healthcare Conference on March 2, 2026, in Boston. The presentation will be accessible via live and archived webcasts on the company's investor relations website.GlobeNewswire Inc. · Feb 20, 2026

BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings' Surgical and Wound Care BusinessBioStem Technologies (OTC:BSEM) announced the closing of its acquisition of BioTissue Holdings' surgical and wound care business for approximately $15 million upfront, with potential milestone payments up to $25 million. The acquisition includes the Neox® and Clarix® product lines, a nationwide sales force, and GPO contracts. The acquired assets generated $29 million in 2025 sales and are expected to contribute positive EBITDA in 2026. Barry Hassett was promoted to Chief Commercial Officer to lead the combined commercial team.Benzinga · Jan 21, 2026

BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care ConferenceBioStem Technologies is introducing American Amnion, a placental-derived biologic for wound care, at the Desert Foot Conference. The product uses proprietary BioRetain technology and demonstrates superior wound closure rates compared to standard treatments, with a focus on improving care for veterans.GlobeNewswire Inc. · Dec 10, 2025

BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot UlcersBioStem Technologies announced successful clinical trial results for its BioRetain® allograft in treating diabetic foot ulcers, demonstrating a 53% healing probability compared to 31% with standard care.GlobeNewswire Inc. · Oct 31, 2025

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” ProgramBioStem Technologies has renewed its sponsorship of the Florida Panthers' 'Heroes Among Us' program for the 13th season, honoring military veterans and healthcare professionals during NHL home games.GlobeNewswire Inc. · Oct 2, 2025

North America Diabetic Foot Ulcer Treatment Market Rises at 5.74% CAGR by 2034The North America diabetic foot ulcer treatment market is expected to grow from USD 1.27 billion in 2024 to USD 2.22 billion by 2034, with a 5.74% CAGR, driven by aging population, R&D advances, and increasing diabetes cases.GlobeNewswire Inc. · Sep 15, 2025

BioStem Technologies Announces Insider Share Purchase by Chairman and Chief Executive OfficerBioStem Technologies' CEO Jason Matuszewski purchased 15,500 shares of company stock valued at approximately $100,000, increasing his total ownership to 1,145,362 shares.GlobeNewswire Inc. · Aug 21, 2025

Ernst & Young (EY) US Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award finalistBioStem Technologies CEO Jason Matuszewski has been named a finalist for the prestigious Entrepreneur Of The Year 2025 Florida Award by Ernst & Young, recognizing his entrepreneurial spirit and the company's impact in the advanced wound care sector.GlobeNewswire Inc. · May 22, 2025

to start trading

BS

BSEMBioStem Technologies, Inc. Common Stock

BSEM

Pay with—

Available Balance0.00

Your PositionYou don't own any BSEM yet.

Related Tickers

Earnings